Plasma concentrations of active simvastatin acid are increased by gemfibrozil

Chemorefractory Rhabdomyosarcoma Treated with Radiotherapy, Bevacizumab, Statins and Surgery and Maintenance with Bevacizumab and Chemotherapy

Lindén, O., Greiff, L., Wahlberg, P., Vinge, E., & n, E. K. E. (2008) · Onkologie · doi:10.1159/000137715 · Cited by 7

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil

Aurinsalo, L., Lapatto‐Reiniluoto, O., Kurkela, M. J., Neuvonen, M., Kiiski, J. I., Niemi, M., Tornio, A., & Backman, J. T. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3610 · Cited by 6

Clinical Relevance: Drug–Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity

Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2006) · doi:10.1002/9780470140505.ch24 · Cited by 6

Drug Transport in the Liver

Ferslew, B. C., Köck, K., & Brouwer, K. L. R. (2014) · doi:10.1002/9781118705308.ch13 · Cited by 6

Uremic Toxins Enhance Statin-Induced Cytotoxicity in Differentiated Human Rhabdomyosarcoma Cells

UCHIYAMA, H., Tsujimoto, M., Shinmoto, T., Ogino, H., Oda, T., Yoshida, T., Furukubo, T., Izumi, S., Yamakawa, T., Tachiki, H., et al. (2014) · Toxins · doi:10.3390/toxins6092612 · Cited by 5

Impact of Pharmacists’ Interventions and Simvastatin Dose Restrictions

Shoulders, B. R., Franks, A. S., Barlow, P. B., Williams, J. D., & Farland, M. Z. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013511323 · Cited by 5

Tendon rupture associated with concomitant simvastatin and gemfibrozil use: Biological and pharmacokinetic implications

Cevallos, E. C., Shaikh, D. H., González, J. R., Sanchez, W., & Patel, M. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2387 · Cited by 5

Combination lipid-lowering therapy in diabetes

Davidson, M. H. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0074-1 · Cited by 4

A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition

Paolo, V. D., Ferrari, F. M., Poggesi, I., & Quintieri, L. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1998453 · Cited by 4

The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drug–Drug Interactions in Humans

Unadkat, J. D., Kirby, B. J., Endres, C. J., & Zolnerciks, J. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_21 · Cited by 4

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Stäuble, C. K., Toma, V., Stammschulte, T., Allemann, S. S., & zu Schwabedissen, H. E. M. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03968-7 · Cited by 4

Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand

Rattanachotphanit, T., Limwattananon, C., & Waleekhachonloet, O. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618820502 · Cited by 3

HMG coenzyme a reductase inhibitors

Klag, M. J. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.14123.x · Cited by 3

Corrigendum: Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach

Liu, S., Wang, Z., Tian, X., & Cai, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.668861 · Cited by 3

A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6

Paolo, V. D., Ferrari, F. M., Veronese, D., Poggesi, I., & Quintieri, L. (2024) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2024.107516 · Cited by 2

Organic anion-transporting polypeptides (OATPs/SLCOs)

Lai, Y. (2013) · Elsevier eBooks · doi:10.1533/9781908818287.353 · Cited by 2

HMG coenzyme-A reductase inhibitors

(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00850-7 · Cited by 2

Pharmacogenetics of SLCO1B1 : Population genetics and effect on statins

Pasanen, M. K. (2008) · Työväentutkimus Vuosikirja · Cited by 2

Recovery Time in a Case of Gemfibrozil and Simvastatin-Associated Rhabdomyolysis

Cummins, D. F., Mackey, M. C., & Baker, E. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e3181ad6078 · Cited by 2

Atteintes musculaires sévères sous statines : bilan des cas notifiés en France jusqu’à fin février 2002 et données concernant les risques liés à la cérivastatine

Andréjak, M., Gras, V., & Caron, J. (2005) · Therapies · doi:10.2515/therapie:2005040 · Cited by 2

Pharmacological Therapy for Cardiovascular Disease

Davidson, M. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_7 · Cited by 2

Clinical Relevance

Marchetti, S., & Schellens, J. H. M. (2014) · doi:10.1002/9781118705308.ch22 · Cited by 2

44 Drugs that affect lipid metabolism

Aursnes, I. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29044-5 · Cited by 1

Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany

Jacob, L., Greiner, R.-A., Luedde, M., & Kostev, K. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001153 · Cited by 1

Fibrates

(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00744-7 · Cited by 1

Drugs for the Skinternist

Landis, M. N., & Adams, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00039-5 · Cited by 1

Rosuvastatin

CHENG, A. Y. Y., & Leiter, L. A. (2004) · Journal of Drug Evaluation · doi:10.3109/14791130400000807 · Cited by 1

LIPID – REGULATING DRUGS

(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50010-7 · Cited by 1

Cytochrome P450: Another Player in the Myocardial Infarction Game?

Sunder‐Plaßmann, R. (2006) · Advances in clinical chemistry · doi:10.1016/s0065-2423(06)43008-0 · Cited by 1

Effects of SLCO1B1 polymorphism on the pharmacokinetics of the oral antidiabetic drugs repaglinide, nateglinide, rosiglitazone, and pioglitazone

Kalliokoski, A. (2008) · Työväentutkimus Vuosikirja · Cited by 1

Effects of Simvastatin on the Growth and Invasion of Anaplastic Thyroid Cancer Cells Lines

Choi, H. J., Kim, T. Y., Kim, E. Y., Kim, W. G., Kim, W. B., & Shong, Y. K. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.4.238 · Cited by 1

Introduction to Drug Transporters

Leung, L. Y., & Oganesian, A. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch6 · Cited by 1

Pharmacokinetic interactions affecting the antidiabetic repaglinide

Kajosaari, L. I. (2006) · Työväentutkimus Vuosikirja

Role of CYP2C8 in the metabolism of montelukast and imatinib : Studies in vitro, in silico and in humans

Filppula, A. M. (2014) · Työväentutkimus Vuosikirja

Skeletal Muscle and Mitochondrial Toxicity

Johnson, T. E. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch7

Effects of induction and inhibition of Cytochrome P-450 enzymes on the pharmacokinetics and pharmacodynamics of oral antidiabetic drugs

Niemi, M. (2001) · Työväentutkimus Vuosikirja

ADME of Cardiovascular Drugs

Liu, H. S., & Voorman, R. L. (2012) · Encyclopedia of Drug Metabolism and Interactions · doi:10.1002/9780470921920.edm041

Introduction to Drug Transporters

Leung, L. Y., & Oganesian, A. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse105

The myotoxicity of statins

Evans, M., & Rees, A. (2002) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200201060-00009

Diabetes mellitus tipo 2. ¿Cómo tratar la dislipemia diabética?

Pérez, A., & Sojo, L. (2005) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(05)73369-6

Endothelial cell-derived microparticles

Hussein, M. N. A. (2008)

Phenotype Standardization for Statin-Induced

Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Bloch, K. M., Fahy, J., Hanson, A., Wadelius, M., & Pirmohamed, M. (2014)

Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships

Honkalammi, J. (2011) · Työväentutkimus Vuosikirja

In vitro approaches in evaluation and prediction of drug-drug interactions involving the inhibition of cytochrome P450 enzymes

Xia, W. (2002) · Työväentutkimus Vuosikirja

Epidemiology of Cytochrome P450-mediated Drug-Drug Interactions

Tirkkonen, T. (2010) · UTUPub (University of Turku)

Comparative Analysis of Clinical and Non-Clinical Pharmacokinetic Interactions of Statins with Other Drugs

Saito, M., Hirata, M., Urano, T., Miyake, S., & Hasegawa, R. (2007) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.33.291

Musculoskeletal Adverse Events Associated with Simvastatin Drug Interactions and Physician Response to Pharmacist Interventions

Siriangkhawut, M. (2015) · วารสารเภสัชศาสตร์อีสาน (Isan Journal of Pharmaceutical Sciences, IJPS)

Drug Interaction of Warfarin with Simvastatin/Gemfibrozil : high levels of ALT/AST, rhabdomyolysis and acute renal failure

Osun, B., & Yoon, H. (2011) · Korean Journal of Clinical Pharmacy

Pharmacokinetics of montelukast and zafirlukast as affected by CYP inhibitors

Karonen, T. (2012) · Työväentutkimus Vuosikirja

Clinical studies on pharmacokinetic drug-drug interactions caused by clopidogrel : focus on CYP2C8-mediated drug metabolism

Itkonen, M. K. (2019) · Työväentutkimus Vuosikirja

Identification and mechanistic investigation of clinically important myopathic drug-drug interactions

Han, X. (2014) · doi:10.7912/c2/311

REFERENCES

(2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00125-2

Drugs that affect lipid metabolism

Aursnes, I. (2002) · Side effects of drugs annual · doi:10.1016/s0378-6080(02)80051-4

News in brief...

&NA; (2000) · Reactions Weekly · doi:10.2165/00128415-200008230-00005

Relationship between Statins Adverse Events and Pharmacokinetic Variables

Finco, A. (2018) · Modern Applications of Bioequivalence & Bioavailability · doi:10.19080/mabb.2018.03.555609

Drugs for the skinternist

Landis, M. N., & Adams, D. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2003-7.00034-0

Reply

Hansten, P. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00637-5

HMG coenzyme-A reductase inhibitors

(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/01014-7

Simvastatin therapy in different subtypes of hypercholesterolemia – a physiologically based modelling approachPreprint

Bartsch, F., Grzegorzewski, J., Pujol, H. L., Tautenhahn, H., & König, M. (2023) · medRxiv · doi:10.1101/2023.02.01.23285358

The effects of co-administering the flavonoids quercetin and biochanin A on simvastatin toxicity in HepG2 cultures

Zechner, J., Britza, S. M., Farrington, R., Byard, R. W., & Musgrave, I. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100209

Relationship between simvastatin pharmacokinetics and muscle toxicity in male mice

Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Fehrenbach, N. B., Fréchard, T., Manivannan, M., Duthaler, U., & Krähenbühl, S. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115688

WITHDRAWN: Comparative Safety of Fibrate Drugs: a Pharmacovigilance Study of Fenofibrate and GemfibrozilPreprint

Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · medRxiv · doi:10.64898/2026.01.01.26343323

Adverse event profiles of fenofibrate and gemfibrozil: a retrospective comparative study and literature synthesis

Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05302-z

Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions

Morse, B. L., Han, B., Alberts, J. J., Posada, M. M., Dickinson, G. L., & Hall, S. D. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01299-8

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Backman, J. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 337

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Schneck, D. W. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 293

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 282